Received Feb 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
I developed vertigo and double vision, 6 weeks after my first Shingrix shot; I developed vertigo and double vision, 6 weeks after my first Shingrix shot; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of vertigo in a patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, 6 weeks after receiving Shingrix, the patient experienced vertigo (Verbatim: I developed vertigo and double vision, 6 weeks after my first Shingrix shot) and double vision (Verbatim: I developed vertigo and double vision, 6 weeks after my first Shingrix shot). The outcome of the vertigo and double vision were not reported. It was unknown if the reporter considered the vertigo and double vision to be related to Shingrix. It was unknown if the company considered the vertigo and double vision to be related to Shingrix. Additional Information: GSK Receipt Date: 03-FEB-2025 The reporter from digital media of GlaxoSmithKline that he/she received first dose of Shingrix vaccine and experienced vertigo and double vision in 6 weeks. The reporter asked that the Vertigo was known side effect of Shingrix. Two months had passed from first vaccination.